Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL).

(2017) M. S. Czuczman et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.

(2017) M. J. Barth et al.   JOURNAL OF CLINICAL ONCOLOGY

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis

(2014) P. V. Beum et al.   JOURNAL OF IMMUNOLOGY

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

(2009) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

(2008) D. Dayde et al.   BLOOD

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

(2008) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY